Thomas G. Wiggans, a director at Jasper Therapeutics ($JSPR), made two open market purchases of company shares in the last year, totaling nearly $100,000. His most recent buy occurred on September 22, 2025. These purchases rank him 2,339th among 4,983 insiders in our database by dollar amount, well below the average of $1.5 million across about 3.3 transactions per insider. Wiggans reported no open market sales during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sept. 22, 2025 | Jasper Therapeutics, Inc. | $JSPR | WIGGANS THOMAS G | Director | P | Voting Common Stock | 41000 | $2.43 | 46,000.0000 | 15,333,962 | 820.00% | 0.27% |
| Sept. 22, 2025 | Jasper Therapeutics, Inc. | $JSPR | WIGGANS THOMAS G | Director | P | Common Stock Warrant (right to buy) | 41000 | $0.00 | 41,000.0000 | 15,333,962 | 9999.99% | 0.27% |
| July 3, 2025 | Jasper Therapeutics, Inc. | $JSPR | WIGGANS THOMAS G | Director | A | Stock Option (right to buy) | 7500 | $0.00 | 7,500.0000 | 15,333,962 | 9999.99% | 0.05% |
| June 5, 2025 | Annexon, Inc. | $ANNX | WIGGANS THOMAS G | Not found | A | Stock Option (Right to Buy) | 55000 | $0.00 | 55,000.0000 | 137,404,145 | 9999.99% | 0.04% |
| June 6, 2024 | Jasper Therapeutics, Inc. | $JSPR | WIGGANS THOMAS G | Director | A | Stock Option (right to buy) | 7500 | $0.00 | 7,500.0000 | 13,334,900 | 9999.99% | 0.06% |
| June 5, 2024 | Annexon, Inc. | $ANNX | WIGGANS THOMAS G | Not found | A | Stock Option (Right to Buy) | 44000 | $0.00 | 44,000.0000 | 75,673,081 | 9999.99% | 0.06% |